Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increase in the prevalence of rare diseases
3.2.1.2 Favorable government policies
3.2.1.3 Growing number of new drug launches
3.2.1.4 Increasing R&D activities for novel therapeutics drugs
3.2.2 Industry pitfalls & challenges
3.2.2.1 Lack of awareness regarding rare disease treatment
3.2.2.2 High cost of the drugs and therapy
3.3 Growth potential analysis
3.4 Clinical trial scenario for rare disease treatment
3.5 Pipeline analysis
3.6 Future market trends
3.7 Technology landscape
3.8 Epidemiology scenario
3.9 Current therapies
3.10 Reimbursement scenario
3.11 Regulatory landscape
3.12 Porter’s analysis
3.13 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategic dashboard
Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)
5.1 Key trends
5.2 Biologics
5.3 Non-biologics
Chapter 6 Market Estimates and Forecast, By Therapeutic Area, 2021 - 2032 ($ Mn)
6.1 Key trends
6.2 Cancer
6.3 Blood-related disorders
6.4 Central nervous system
6.5 Respiratory disorders
6.6 Musculoskeletal disorders
6.7 Cardiovascular disorders
6.8 Other therapeutic areas
Chapter 7 Market Estimates and Forecast, By Patient, 2021 - 2032 ($ Mn)
7.1 Key trends
7.2 Adult
7.3 Pediatric
Chapter 8 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)
8.1 Key trends
8.2 Oral
8.3 Injectable
Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Poland
9.3.7 Switzerland
9.3.8 Sweden
9.3.9 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Indonesia
9.4.7 Thailand
9.4.8 Vietnam
9.4.9 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.5.4 Chile
9.5.5 Colombia
9.5.6 Peru
9.5.7 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
9.6.4 Israel
9.6.5 Egypt
9.6.6 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 AbbVie Inc.
10.2 Alexion Pharmaceuticals, Inc.
10.3 Amgen Inc
10.4 AstraZeneca PLC
10.5 Baxter International
10.6 Bayer AG
10.7 Biogen
10.8 Bristol-Myers Squibb
10.9 Eli Lilly and Company
10.10 F. Hoffmann La Roche Ltd
10.11 GSK plc
10.12 Johnson & Johnson
10.13 Merck & Co. Inc.
10.14 Novartis AG
10.15 Novo Nordisk
10.16 Pfizer, Inc.
10.17 Pharmacyclics LLC
10.18 Sanofi SA
10.19 Seagen Inc.
10.20 Takeda Pharmaceutical Company Ltd.
10.21 Vertex Pharmaceutical Inc.
